Landos Biopharma, Inc.
NASDAQ:LABP
22.93 (USD) • At close May 23, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 18 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0.577 | 0.196 | 0.137 | 0.103 | 0 |
| Gross Profit
| 0 | -0.577 | 17.804 | -0.137 | -0.103 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0.989 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 11.999 | 25.68 | 41.564 | 25.338 | 11.812 | 6.803 |
| General & Administrative Expenses
| 10.728 | 14.881 | 15.252 | 5.338 | 1.478 | 1.136 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 10.728 | 14.881 | 15.252 | 5.338 | 1.478 | 1.136 |
| Other Expenses
| 0 | 1.285 | 0.394 | 0 | 0.16 | 2.005 |
| Operating Expenses
| 22.727 | 40.561 | 56.816 | 30.676 | 13.29 | 7.939 |
| Operating Income
| -22.727 | -40.561 | -38.816 | -30.676 | -13.29 | -7.939 |
| Operating Income Ratio
| 0 | 0 | -2.156 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.792 | 1.285 | 0.394 | 0.532 | -0.177 | 1.895 |
| Income Before Tax
| -21.935 | -39.276 | -38.422 | -30.144 | -13.467 | -6.044 |
| Income Before Tax Ratio
| 0 | 0 | -2.135 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -1.285 | -0.196 | 0 | 0.464 | 1.899 |
| Net Income
| -21.935 | -37.991 | -38.226 | -30.144 | -13.931 | -6.044 |
| Net Income Ratio
| 0 | 0 | -2.124 | 0 | 0 | 0 |
| EPS
| -3.5 | -9.44 | -9.5 | -7.51 | -3.47 | -2.62 |
| EPS Diluted
| -3.5 | -9.44 | -9.5 | -7.51 | -3.47 | -2.62 |
| EBITDA
| -22.727 | -40.561 | -38.816 | -30.084 | -13.027 | -5.854 |
| EBITDA Ratio
| 0 | 0 | -2.156 | 0 | 0 | 0 |